Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Radiotherapy Advances in Paediatric Medulloblastoma Treatment.

Padovani L, Horan G, Ajithkumar T.

Clin Oncol (R Coll Radiol). 2019 Mar;31(3):171-181. doi: 10.1016/j.clon.2019.01.001. Epub 2019 Jan 14.

PMID:
30655168
2.
3.

Chemotherapy for children with medulloblastoma.

Michiels EM, Schouten-Van Meeteren AY, Doz F, Janssens GO, van Dalen EC.

Cochrane Database Syst Rev. 2015 Jan 1;1:CD006678. doi: 10.1002/14651858.CD006678.pub2. Review.

PMID:
25879092
4.

Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.

Carrie C, Grill J, Figarella-Branger D, Bernier V, Padovani L, Habrand JL, Benhassel M, Mege M, Mahé M, Quetin P, Maire JP, Baron MH, Clavere P, Chapet S, Maingon P, Alapetite C, Claude L, Laprie A, Dussart S.

J Clin Oncol. 2009 Apr 10;27(11):1879-83. doi: 10.1200/JCO.2008.18.6437. Epub 2009 Mar 9.

PMID:
19273707
5.

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ.

Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.

PMID:
17012043
6.

Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.

Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, Jones RM, MacDonald SM, Pulsifer MB, Lavally B, Abrams AN, Huang MS, Marcus KJ, Tarbell NJ.

Lancet Oncol. 2016 Mar;17(3):287-98. doi: 10.1016/S1470-2045(15)00167-9. Epub 2016 Jan 30.

PMID:
26830377
7.

Medulloblastoma.

von Hoff K, Rutkowski S.

Curr Treat Options Neurol. 2012 Aug;14(4):416-26. doi: 10.1007/s11940-012-0183-8.

PMID:
22622599
8.

Late toxicity following craniospinal radiation for early-stage medulloblastoma.

Christopherson KM, Rotondo RL, Bradley JA, Pincus DW, Wynn TT, Fort JA, Morris CG, Mendenhall NP, Marcus RB Jr, Indelicato DJ.

Acta Oncol. 2014 Apr;53(4):471-80. doi: 10.3109/0284186X.2013.862596. Epub 2014 Feb 24.

PMID:
24564687
9.

Radiotherapy for Adult Medulloblastoma: Evaluation of Helical Tomotherapy, Volumetric Intensity Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy and the Results of Helical Tomotherapy Therapy.

Zong-Wen S, Shuang-Yan Y, Feng-Lei D, Xiao-Long C, Qinglin L, Meng-Yuan C, Yong-Hong H, Ting J, Qiao-Ying H, Xiao-Zhong C, Yuan-Yuan C, Ming C.

Biomed Res Int. 2018 Mar 21;2018:9153496. doi: 10.1155/2018/9153496. eCollection 2018.

10.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.

Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1.

11.

Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.

Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D'Angio G, Wechsler-Jentzsch K, et al.

J Neurosurg. 1994 Nov;81(5):690-8.

PMID:
7931615
12.

Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol.

von Bueren AO, Friedrich C, von Hoff K, Kwiecien R, Müller K, Pietsch T, Warmuth-Metz M, Hau P, Benesch M, Kuehl J, Kortmann RD, Rutkowski S.

Eur J Cancer. 2015 Nov;51(16):2434-43. doi: 10.1016/j.ejca.2015.06.124. Epub 2015 Aug 5.

PMID:
26254812
13.

Radiotherapeutic management of medulloblastoma.

Paulino AC.

Oncology (Williston Park). 1997 Jun;11(6):813-23; discussion 823, 827-8, 831. Review.

14.

Low-dose craniospinal radiation therapy for medulloblastoma.

Halberg FE, Wara WM, Fippin LF, Edwards MS, Levin VA, Davis RL, Prados MB, Wilson CB.

Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):651-4.

PMID:
2004939
15.

Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy.

Wara WM, Le QT, Sneed PK, Larson DA, Prados MD, Levin VA, Edwards MS, Weil MD.

Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):551-6.

PMID:
7928485
16.

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.

Saran FH, Driever PH, Thilmann C, Mose S, Wilson P, Sharpe G, Adamietz IA, Böttcher HD.

Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):959-67. Review.

PMID:
9869216
17.

Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children.

Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB.

JAMA Oncol. 2016 Dec 1;2(12):1574-1581. doi: 10.1001/jamaoncol.2016.2547. Erratum in: JAMA Oncol. 2016 Dec 1;2(12 ):1661.

PMID:
27491009
18.

Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children.

Yuh GE, Loredo LN, Yonemoto LT, Bush DA, Shahnazi K, Preston W, Slater JM, Slater JD.

Cancer J. 2004 Nov-Dec;10(6):386-90.

PMID:
15701271
19.

Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.

Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7. Epub 2007 Sep 24.

20.

Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy.

Ricardi U, Corrias A, Einaudi S, Genitori L, Sandri A, di Montezemolo LC, Besenzon L, Madon E, Urgesi A.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1287-94.

PMID:
11483340

Supplemental Content

Support Center